英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

angriest    音标拼音: ['æŋgriəst]
angry的最高级

angry的最高级

Angry \An"gry\, a. [Compar. {Angrier}; superl. {Angriest}.] [See
{Anger}.]
1. Troublesome; vexatious; rigorous. [Obs.]
[1913 Webster]

God had provided a severe and angry education to
chastise the forwardness of a young spirit. --Jer.
Taylor.
[1913 Webster]

2. Inflamed and painful, as a sore.
[1913 Webster]

3. Touched with anger; under the emotion of anger; feeling
resentment; enraged; -- followed generally by with before
a person, and at before a thing.
[1913 Webster]

Be not grieved, nor angry with yourselves. --Gen.
xlv. 5.
[1913 Webster]

Wherefore should God be angry at thy voice?
--Eccles. v.
6.
[1913 Webster]

4. Showing anger; proceeding from anger; acting as if moved
by anger; wearing the marks of anger; as, angry words or
tones; an angry sky; angry waves. "An angry countenance."
--Prov. xxv. 23.
[1913 Webster]

5. Red. [R.]
[1913 Webster]

Sweet rose, whose hue, angry and brave. --Herbert.
[1913 Webster]

6. Sharp; keen; stimulated. [R.]
[1913 Webster]

I never ate with angrier appetite. --Tennyson.
[1913 Webster]

Syn: Passionate; resentful; irritated; irascible; indignant;
provoked; enraged; incensed; exasperated; irate; hot;
raging; furious; wrathful; wroth; choleric; inflamed;
infuriated.
[1913 Webster]


请选择你想看的字典辞典：
单词字典翻译
Angriest查看　Angriest　在百度字典中的解释百度英翻中〔查看〕
Angriest查看　Angriest　在Google字典中的解释Google英翻中〔查看〕
Angriest查看　Angriest　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Yuviwel: Uses, Dosage, Side Effects, Warnings - Drugs. com
    Yuviwel is used to increase linear growth in children 2 years and older with achondroplasia with open epiphyses It is given once-weekly by subcutaneous injection Learn about side effects, the mechanism of action, and administration
  • Navepegritide (Yuviwel®) for Children with Achondroplasia . . .
    Navepegritide (Yuviwel®) for Children with Achondroplasia: New Drugs and Therapeutics Written by Anna Ryabets-Lienhard, DO Edited by Neha Patel, DO and Emily Breidbart, MD On February 27th, 2026, the FDA approved Navepegritide (Yuviwel®), a C-natriuretic peptide (CNP) analog prodrug developed by Ascendis Pharmaceuticals using TransCon® CNP technology 1 The once‑weekly subcutaneous therapy
  • Achondroplasia Treatment: New 2026 FDA Approval | Medaptly
    Achondroplasia Treatment: FDA Approves Yuviwel as First Once-Weekly Therapy for Children On February 27, 2026, Yuviwel (navepegritide) became the first once-weekly achondroplasia treatment cleared by the FDA for children ages 2 and older Pediatricians now have an alternative to daily vosoritide, with phase 2b data showing a 1 49 cm year growth velocity advantage over placebo
  • FDA Grants Accelerated Approval to Yuviwel - Drugs. com
    “The approval of once-weekly Yuviwel is a major step forward in the treatment of children with achondroplasia, giving physicians for the first time the option of prescribing a once-weekly medicine backed by compelling efficacy and excellent tolerability data from three randomized, double-blind, placebo-controlled clinical trials,” said
  • Yuviwel for Achondroplasia - WebMD
    Yuviwel is an FDA-approved medicine to help improve growth rates in certain people with achondroplasia Here’s how it works
  • FDA Approves YUVIWEL for Children with Achondroplasia - Bi
    The FDA has approved YUVIWEL for children with achondroplasia, offering a once-weekly treatment option Available in Q2 2026
  • YUVIWEL treats achondroplasia with continuous FGFR3 exposure
    YUVIWEL is designed to provide continuous exposure of active CNP to receptors throughout the body to counteract the overactive FGFR3 signaling associated with achondroplasia 💉 Achondroplasia
  • Ascendis Pharma Gains FDA Approval for Yuviwel First Weekly . . .
    Ascendis Pharma won FDA approval for Yuviwel, its first once-weekly treatment for children aged two and older with achondroplasia, earning a Rare Pediatric Disease Priority Review Voucher Yuviwel will be available to U S prescribing physicians in early Q2 2026, bolstering the company’s rare pediatric portfolio
  • Ascendis Pharma’s YUVIWEL® (NASDAQ:ASND) Receives FDA . . .
    Jan Mikkelsen, President and Chief Executive Officer at Ascendis Pharma, said that they are confident in YUVIWEL’s potential to transform the treatment of achondroplasia and are deeply grateful to patients, clinicians, and advocates for their many contributions to this important milestone
  • FDA Approves Once-Weekly YUVIWEL® (navepegritide) for . . .
    “The approval of once-weekly YUVIWEL is a major step forward in the treatment of children with achondroplasia, giving physicians for the first time the option of prescribing a once-weekly medicine backed by compelling efficacy and excellent tolerability data from three randomized, double-blind, placebo-controlled clinical trials,” said





中文字典-英文字典  2005-2009